Effects of phenothiazine drugs on serum levels of apolipoproteins and lipoproteins in schizophrenic subjects

Acta Pharmacologica Sinica

Volumn 24, Issue 10, 2003, Pages 1001-1005+1061

  Wen, Fang ^a   Tan, Jie ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Antipsychotic agents; Apolipoproteins; Lipoproteins; Phenothiazines; Schizophrenia

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHLORPROMAZINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLUOROSCOPY; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SCHIZOPHRENIA; TURBIDIMETRY;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, HDL; DEMENTIA, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTHIAZINES; SCHIZOPHRENIA; TRIGLYCERIDES;

EID: 0141891912     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Wen F, Li QY, Bai XG, Wan JC. The effect of phenothiazine drugs on schizophrenia in serum HDL-C and cholesterol in its subcomponents. Chin J Pharm 1990; 25: 345-8.
2. Wen F, Cheng ZL, Bai XG, Zhang DX, Lin Q, Wan JC. The effect of phenothiazine drugs on serum apoprotein level. Chin J Psychiratry Sci 1998; 34: 108-10.
3. Ke SF, Yi HL, Li CY, Yu MY. The effect of antipsychotics on blood lipid. Shanghai J Ment Sci 1996; 8: 34-5.
4. Sasaki J, Kumage G, Sata T, Ikeda M, Tsutsumic S, Arakawa K. Seasonal variation of serum high density lipoprotein cholesterol levels in men. Atherosclerosis 1983; 48: 167-72.
5. Saski J, Kumage G, Sata T, Kuramitsu M, Arakawa K. Decreased concetion of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines. Atherosclerosis 1984; 51: 163-9.
6. Kukita H, Hamada M, Hiwada K, Kokubu T. Clinical significance of serum of apolipoprotein A-I, A-II, and B in hypertriglyceridemic male patients without coronary artery disease. Atherosclerosis 1985; 55: 143-9.
7. Matsuda M, Miyahare T, Murai A, FuJimoto N, Kameyama M. Lipoprotein abnor-malitiesin survivors of cerebral infarction with a special reference to apolipoproteins and triglyceride-rich lipoproteins. Atherosclerosis 1987; 68: 131-4.
8. Wen F, Wan JC, Hu ZX, He B. The study of thrombosis and serum apoprotein B contents. Chin J Neuropsycho 1990; 16: 1-2.
9. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992; 93: 189-99.
10. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11: 2-14.
11. Davignon J, Cohn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis 1996; 124 Suppl: S57-64.
12. Tribble DL, Krauss RM, Lansberg MG, Thiel PM, Joren J, Mvan DB. Greater oxidative susceptibility of the surface monolayer in small dense LDL may contribute to differences in copper-induced oxidation among LDL density subfractions. J Lipid Res 1995; 36: 662-8